Literature DB >> 10767376

Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.

Y Ohsaki1, S Tanno, Y Fujita, E Toyoshima, S Fujiuchi, Y Nishigaki, S Ishida, A Nagase, N Miyokawa, S Hirata, K Kikuchi.   

Abstract

To determine whether cancer patients with tumor suppressor gene abnormality survive for a shorter time when their growth was stimulated by growth factors, we examined 290 non-small cell lung cancer (NSCLC) specimens for p53 and epidermal growth factor receptor (EGFR) protein expressions using immunohistochemical staining. The distribution of cases by pathological stage of tumor was 155 cases of stage I, 30 cases of stage II, 96 cases of stage III and 9 cases of stage IV. Pathological types were 142 adenocarcinomas, 127 squamous cell carcinomas, 17 large cell carcinomas and 4 other types of malignancy. Immunohistochemical staining was performed on the formalin fixed, paraffin-embedded materials with monoclonal antibodies DO-7 and clone EGFR.133. positive staining for EGFR was seen in 124 (42.8%) cases. More EGFR positive cases were found in squamous cell carcinomas than in non-squamous cell carcinomas (p=0.0121). Staining for p53 protein was observed in 147 (50.7%) specimens. Multivariate proportional hazard model analyses revealed EGFR protein expression as a risk factor in the patients with NSCLC (p=0.0240). Patients negative for both EGFR and p53 survived for a longer period of time (p=0.0427).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767376     DOI: 10.3892/or.7.3.603

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  62 in total

1.  Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.

Authors:  Dongwei Zhang; Ana M Tari; Ugur Akar; Banu K Arun; Tiffany A LaFortune; Rene Nieves-Alicea; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2010-11-02       Impact factor: 6.261

2.  EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer.

Authors:  David E Gerber
Journal:  Drug Dev Res       Date:  2008-12-09       Impact factor: 4.360

3.  Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.

Authors:  Katharina Kuester; Andreas Kovar; Christian Lüpfert; Brigitte Brockhaus; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.

Authors:  Gillian Bethune; Drew Bethune; Neale Ridgway; Zhaolin Xu
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

Review 5.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

6.  Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

Authors:  Kimio Yonesaka; Kreshnik Zejnullahu; Neal Lindeman; Alison J Homes; David M Jackman; Feng Zhao; Andrew M Rogers; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

7.  Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer.

Authors:  Ching-Hsiung Lin; Kun-Tu Yeh; Ya-Sian Chang; Nicholas C Hsu; Jan-Gowth Chang
Journal:  J Biomed Sci       Date:  2010-05-12       Impact factor: 8.410

8.  A pilot characterization of human lung NSCLC by protein pathway activation mapping.

Authors:  Angela Zupa; Giuseppina Improta; Alessandra Silvestri; Elisa Pin; Jianghong Deng; Michele Aieta; Pellegrino Musto; Donato Nitti; Enzo Mammano; Lance Liotta; Claudio Belluco; Julia Wulfkuhle; Emanuel Petricoin
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

9.  Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.

Authors:  Giuseppe Giaccone; Renee B Iacona; Abderrahim Fandi; Mette Janas; Judith S Ochs; Roy S Herbst; David H Johnson
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-12       Impact factor: 4.553

Review 10.  A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.

Authors:  Adam Yagui-Beltrán; David M Jablons
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-08       Impact factor: 1.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.